BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
158.00
+1.80 (+1.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close156.20
Open156.60
Bid149.00 x 800
Ask180.00 x 1300
Day's Range154.55 - 159.00
52 Week Range91.15 - 236.17
Volume349,840
Avg. Volume891,965
Market Cap8.557B
Beta2.71
PE Ratio (TTM)N/A
EPS (TTM)-9.51
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est211.07
Trade prices are not sourced from all markets
  • What Does NovoCure’s Valuation Trend Indicate?
    Market Realist3 days ago

    What Does NovoCure’s Valuation Trend Indicate?

    NovoCure’s (NVCR) net financial expenses increased from $2.18 million in the second quarter of 2017 to $2.86 million in the second quarter. NovoCure’s income tax expenses also increased from $3.46 million in the second quarter of 2017 to $5.56 million in the second quarter.

  • Market Exclusive4 days ago

    Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail

    Futures Up on China-U.S. Trade Talks, China at New 52-Week Lows Washington sent an invitation to Beijing for trade talks in late August, and the Chinese have responded in kind. They plan to send their vice minister of commerce to discuss the situation, and U.S. futures are up on the news. Not so much for […] The post Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musk’s Tail appeared first on Market Exclusive.

  • How Analysts Rate Editas Medicine and Peers in August
    Market Realist10 days ago

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.

  • Motley Fool10 days ago

    Carl Icahn Fires Shots at Express Scripts

    Billionaire activist-investor Carl Icahn thinks Cigna’s planned tie-up with Express Scripts is a big blunder.

  • Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
    Zacks12 days ago

    Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges

    The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.

  • Expectations from BeiGene’s Q2 2018 Earnings
    Market Realist13 days ago

    Expectations from BeiGene’s Q2 2018 Earnings

    BeiGene (BGNE) is a clinical-stage biopharmaceutical company that develops molecularly targeted and immuno-oncology drugs for cancer. BeiGene also markets the drugs Abraxane, Revlimid, and Vidaza in China under its licensing agreement with Celgene (CELG).

  • ACCESSWIRE13 days ago

    Today's Research Reports on Trending Tickers: Spark Therapeutics and bluebird bio

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...

  • Investor's Business Daily14 days ago

    Can These Biotech Companies Catch Novartis, Gilead In CAR-T?

    Regeneron Pharmaceuticals is investing $100 million in Bluebird Bio in an immuno-oncology collaboration that could rival the likes of Novartis and Gilead Sciences.

  • Investor's Business Daily14 days ago

    Stocks Slip As Intel Downgrade Crimps Dow, Qualcomm Upgraded

    Stock futures opened in the red Monday, as chip stocks were active on analyst actions and Bluebird Bio surged on a development deal.

  • bluebird bio Prepares Its "Transition to a Commercial Company"
    Motley Fool14 days ago

    bluebird bio Prepares Its "Transition to a Commercial Company"

    The biotech expects to file a marketing application with EU regulators by the end of the year.

  • Analysts Are Mostly Positive on Neurocrine Biosciences in August
    Market Realist14 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences in August

    In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.

  • How Neurocrine Biosciences Performed in the Second Quarter
    Market Realist14 days ago

    How Neurocrine Biosciences Performed in the Second Quarter

    Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.

  • Barrons.com14 days ago

    Small Biotechs See Big Gains as Bluebird, Intercept Fly

    Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price.  The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years.  Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.

  • Why Is Bluebird Bio (BLUE) Stock Gaining Today?
    Zacks14 days ago

    Why Is Bluebird Bio (BLUE) Stock Gaining Today?

    Shares of Bluebird Bio (BLUE) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN). The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.

  • What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
    Market Realist14 days ago

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.

  • Business Wire14 days ago

    bluebird bio and Regeneron Announce Collaboration to Discover, Develop and Commercialize New Cell Therapies for Cancer

    bluebird bio, Inc. (NASDAQ: BLUE) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. The collaborators will specifically leverage Regeneron’s VelociSuite® platform technologies for the discovery and characterization of fully human antibodies, as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides, and bluebird bio will contribute its field-leading expertise in gene transfer and cell therapy. “The collaboration with Regeneron complements bluebird bio’s growing immuno-oncology development portfolio, which includes clinical and pre-clinical CAR T and T cell receptor programs,” said Philip Gregory, D.Phil., Chief Scientific Officer of bluebird bio.

  • Business Wire17 days ago

    bluebird bio to Present Updated Data for Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy at SSIEM 2018 Symposium

    − Data Include Updates from Phase 2/3 Starbeam Study of Lenti-D for Cerebral Adrenoleukodystrophy and Initial Data from Ongoing Observational Study of Al

  • bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss
    Zacks17 days ago

    bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss

    bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.

  • Bluebird Bio Misses Analysts’ Estimates in Q2 2018
    Market Realist17 days ago

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.

  • Business Wire17 days ago

    bluebird bio to Present at the 2018 Wedbush PacGrow Healthcare Conference

    bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the 2018 Wedbush PacGrow Healthcare Conference, Tuesday, August 14, at 8:35 a.m. ET at the Parker New York Hotel, New York City. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conference.

  • Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates
    Zacks18 days ago

    Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of -26.52% and -28.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire18 days ago

    bluebird bio Reports Second Quarter 2018 Financial Results and Highlights Operational Progress

    - Lenti-D™ granted Priority Medicines designation from European Medicines Agency and Breakthrough Designation from U.S. Food and Drug Administration in cerebral

  • What Analysts Recommend for Bluebird Bio Stock
    Market Realist20 days ago

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.” 

  • Bluebird Bio’s Q2 2018 Earnings: Analysts’ Estimates
    Market Realist20 days ago

    Bluebird Bio’s Q2 2018 Earnings: Analysts’ Estimates

    Clinical-stage biotechnology company Bluebird Bio (BLUE) is set to release its Q2 2018 results tomorrow. The company has research and development collaborations with Celgene (CELG), TC BioPharm, Lonza, MediGene, and Apceth Biopharma.

  • Business Wire24 days ago

    bluebird bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    bluebird bio, Inc. (BLUE) today announced the closing of its previously announced underwritten public offering of 3,892,308 shares of its common stock, including 507,692 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $162.50 per share. Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen acted as joint book-running managers and Wells Fargo Securities acted as co-manager of the offering. The shares were offered by bluebird bio pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC).